PDCD1 and lung adenocarcinoma: In mouse models of lung adenocarcinoma, Koyama et al. observed that in tumors which progressed following initial response to anti-PD-1 therapy, there was an upregulation of other immune checkpoint receptors, particularly TIM-3, on PD-1 antibody-bound T cells.